- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05893316
UroCAD per la valutazione dell'ematuria: uno studio prospettico multicentrico
Valutazione dell'ematuria mediante sequenziamento dell'intero genoma del DNA cellulare esfoliato nelle urine, uno studio prospettico multicentrico
Hematuria is recognized as an important sigh of potential urinary tract malignancy. Therefore, understanding the disease processes and discovering the potential urothelial carcinoma (UC) underlying this important sign is critical. Cystoscopy, urine cytology and imaging are most reliable methods for UC diagnosis, but certain drawbacks exist for these methods, such as invasiveness or inaccuracy. Chromosomal instability (CIN) is a hallmark of human cancer, and it's related with tumor stage and grade. Previous research has proved that analyzing CIN of the DNA extracted from urothelial cells in urine samples seems a promising method for detecting UC. Here the investigators intend to assess CIN's performance for hematuria evaluation.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Hematuria is defined as the presence of 3 or more red blood cells per high-power field (RBC/HPF) under microscopic examination of the urine, which is an important sigh of genitourinary system disease, especially UC. Several methods can be adopted for hematuria evaluation. Cystoscopy is a key component of the hematuria evaluation because it is a reliable way to evaluate the bladder and urethra. Biopsy can also be performed through cystoscopy, making it the "gold standard" for bladder cancer diagnosis. Despite its high reliability and accuracy, it's an invasive examination related with complications such as injury to the urethra, infection, and discomfort. Flat lesions may also be omitted under cystoscopy. Urine cytology is another important method for UC evaluation, but it has a sensitivity of only 15.8%-54.5%.
CIN refers to the ongoing acquisition of genomic alterations, it can range from point mutations to small-scale genomic alterations and gross chromosomal rearrangements. 60%-80% of human tumors exhibit chromosomal abnormalities suggestive of CIN. CIN is presented in UC and it has been adopted as a diagnostic method for UC, such as UroVysion test. Previously, CIN detected by low-coverage whole genome sequencing proved to be a reliable method for UC diagnosis and was named as Urine Exfoliated Cells Copy Number Aberration Detector (UroCAD). In this prospective, multi-canter, observational clinical trial, the investigators intend to assess the possibility of UroCAD as an additional diagnostic tool for hematuria patients by collecting and analyzing 30 ml of urine sample from hematuria patient across 5 centers.
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Cina, 200433
- Changhai Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Patients presented with hematuria (≥ 3 RBCs/HPF) and patients with malignancy other than urothelial carcinoma in Changhai Hospital, Tongji Hospital, Renji Hospital, First Affiliated Hospital of Xian Jiaotong University, and Gulou Hospital.
Descrizione
Inclusion Criteria:
-
Participants aged ≥ 18 years and signed informed consent form.
-
Participants presented with hematuria (≥ 3 RBCs/HPF) and meet one of the following criteria:
- Patients recommended to undergo cystoscopy or ureteroscopy;
- Patients with treatment-naïve, pathology-confirmed urothelial carcinoma;
- Patients diagnosed with benign genitourinary disease.
-
Participants diagnosed with cancer other than urothelial carcinoma.
Exclusion Criteria:
- Participants with history of urothelial carcinoma.
- Participants with urothelial carcinoma accompanied by other malignancy.
- Individuals unwilling to sign the consent form or unwilling to provide urine sample for test or quality of urine sample is poor.
- Patients unsuitable for this clinical trial.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
Hematuria patients
Hematuria patients (≥ 3 RBCs/HPF) with treatment-naïve, pathology-confirmed urothelial carcinoma or benign genitourinary system disease or with undetermined lesion presented with hematuria. |
The level of CIN The extracted DNA from urine exfoliated cells will be analyzed by UroCAD to determine the level of CIN. |
|
Non-hematuria patients
Patients without hematuria and diagnosed with pathology-confirmed cancer other than urothelial cancer. |
The level of CIN The extracted DNA from urine exfoliated cells will be analyzed by UroCAD to determine the level of CIN. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
sensitivity
Lasso di tempo: through study completion, an average of 8 months
|
Comparison of the sensitivity of the UroCAD analysis versus clinically-acceptable threshold, defined as 75%. |
through study completion, an average of 8 months
|
|
specificity
Lasso di tempo: through study completion, an average of 8 months
|
Comparison of the specificity of the UroCAD analysis versus clinically-acceptable threshold, defined as 95%. |
through study completion, an average of 8 months
|
|
Sensitivity among hematuria patients
Lasso di tempo: through study completion, an average of 8 months
|
Sensitivity of UroCAD in detecting urothelial carcinoma among hematuria patients |
through study completion, an average of 8 months
|
|
Specificity among hematuria patients
Lasso di tempo: through study completion, an average of 8 months
|
Specificity of UroCAD in detecting urothelial carcinoma among hematuria patients |
through study completion, an average of 8 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Comparison of Sensitivity
Lasso di tempo: through study completion, an average of 8 months
|
Comparison of the sensitivity of the UroCAD analysis versus urine cytology |
through study completion, an average of 8 months
|
|
Comparison of Specificity
Lasso di tempo: through study completion, an average of 8 months
|
Comparison of the Specificity of the UroCAD analysis versus urine cytology |
through study completion, an average of 8 months
|
Collaboratori e investigatori
Pubblicazioni e link utili
Pubblicazioni generali
- Sansregret L, Vanhaesebroeck B, Swanton C. Determinants and clinical implications of chromosomal instability in cancer. Nat Rev Clin Oncol. 2018 Mar;15(3):139-150. doi: 10.1038/nrclinonc.2017.198. Epub 2018 Jan 3.
- McDougal, W. Scott, et al. Campbell-Walsh urology 11th Edition review e-book. Elsevier Health Sciences, 2015.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Processi patologici
- Neoplasie
- Malattie urogenitali maschili
- Malattie urologiche
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Disturbi della minzione
- Neoplasie per tipo istologico
- Emorragia
- Neoplasie, ghiandolari ed epiteliali
- Carcinoma
- Condizioni patologiche, segni e sintomi
- Carcinoma, cellula di transizione
- Ematuria
Altri numeri di identificazione dello studio
- CH-Hematuria-CIN
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Individual participant data are not public for privacy protection purpose. Data without private information may be provided on request.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .